Immutep Ltd has released a press release.
Immutep reports promising data from INSIGHT-003 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Immutep
- Webcast slides for new Efti clinical data in 1st line NSCLC
- Excellent Overall Survival in Non-Small Cell Lung Cancer
- Immutep announces publication of ESMO 2023 abstracts
- Commercial Scale Manufacturing of Efti for Clinical Trials
- Appendix 4E & 2023 Full Year Statutory Accounts
Later from Immutep
- New Biomarker Data from TACTI-002 trial in 1st line NSCLC
- Lead-in phase completed for ph2/3 trial in Breast Cancer
- Immutep Completes Enrolment for TACTI-003 Phase IIb Trial
- Immutep receives A$2.6 million French R&D Tax Incentive
- PEI provides constructive feedback for ph3 lung cancer trial
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep